The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma - sprookjes - yvandenbroek - TriplyDB

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

http://www.wikidata.org/entity/Q28193895

about

Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy Evidence-based case report: multiple thrombotic episodes associated with lenalidomide and dexamethasone therapy for multiple myeloma Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR)Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance Thrombosis in multiple myeloma Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma Adverse effects of thalidomide administration, in patients with myeloma multiplex?An absence of platelet activation following thalidomide treatment in vitro or in vivo.Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330.Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia.Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma.Pharmacotherapy of multiple myeloma.Thalidomide in multiple myeloma: past, present and future.Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology Thromboembolic events with lenalidomide-based therapy for multiple myeloma Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis.Treatment of relapsed and refractory myeloma.Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study.Neglected respiratory toxicity caused by cancer therapy.A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines Multifocal Arterial Thrombosis during Thalidomide Therapy: Case Report and Review of the Literature.State-of-the-Art Management of Complications of Myeloma and Its Treatment.Anticoagulant use in cancer patients.Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.Guidelines for supportive care in multiple myeloma 2011.Thrombosis in multiple myeloma (MM).Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence.Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications.Thromboembolic risk in hematological malignancies.Comparing venous thromboembolism prophylactic strategies for ambulatory multiple myeloma patients on immunomodulatory drug therapy.Increased risk of arterial thromboembolic events with combination lenalidomide/dexamethasone therapy for multiple myeloma.Safety and efficacy of primary thromboprophylaxis in cancer patients.

P2860

Q24194257-B37563F4-FABD-4EE8-94E8-C6777E848B04 Q26823292-7C2A428F-FA22-491F-8400-22A616E19430 Q26995284-F67ED09D-097C-4F2B-B1B5-F1890E2641DD Q27008491-47C49CEB-E5BE-47E1-ACD7-24A8D4C3C3BE Q28219961-3A7533A7-283D-4723-8EB9-30957D5A713F Q33410297-C3681FCF-AAFE-4B65-9AFC-5C2FCAD1FB08 Q33669639-09C0AFAE-1F44-405C-91CF-E39040763168 Q33829306-DACC293C-09EB-4AB6-B83B-D3606DA08622 Q33931754-66388483-9690-4E04-9701-05EA9815640F Q34546366-06EFC9C1-D5E6-4A89-B129-A52364B53E4F Q35947899-44BEDA6D-93D3-4F3E-94F2-AADD26CDE2B2 Q36149549-93F94D37-5946-455D-AA28-198171B9B3C6 Q36420952-16995C16-D0B8-44F2-9414-8AE89AC22434 Q36429735-5BE51423-2499-47C7-B94F-D03B1ECCB053 Q36616493-68D2B854-F8E9-473F-8FF1-42EEF83FB000 Q36697556-9374B7D2-D12E-49E4-A808-F186D3DF3C93 Q36963203-9609E4B8-43A5-4027-98B0-A91CDFA86A6A Q37038367-033BD12B-35BE-4AF8-987C-1A7726511E8E Q37038711-14ECF958-C274-40D0-8C8F-361B7DF055FF Q37190522-744F787A-9530-4EA7-80B3-C631A47B7222 Q37209929-83771753-ECBA-4AB1-8451-DEB33C2E8069 Q37239890-3AA6BD89-842C-44A9-9878-2D54A718C8DA Q37310407-E5F7044F-1A7E-4DDB-B47A-56BB2D5A78CB Q37362054-663A4AEC-4B11-4612-980E-7C1A79ACF676 Q37429804-6E75CDF4-7B43-411D-95C8-80F64DDD916C Q37451156-33683CCD-542A-4905-8C0A-B6AF432CC5AA Q37454445-F3CBF4C7-1F31-4E19-AFD0-B01B3949FACC Q37590688-F45448C0-8542-46DB-BF17-FA2F1D8A8154 Q37776662-57DB30D5-7FDD-4E93-B3D6-4F8501F17259 Q37831345-E250D0A0-93ED-428A-B8EE-C0B79576C9F5 Q37831402-99F630F0-DC55-4E3D-B3B5-92DC90B8328C Q37868637-431E36EA-3C99-4656-B95D-E8215A7C3D83 Q38003019-4C38D254-53D3-4BCA-8736-A79147BD0EA0 Q38035031-5AB516DA-E144-4CF4-A589-89E2D280C045 Q38065298-E145A44E-03D4-4200-B5EE-DBD4479379A5 Q38230423-A4267795-695D-42E5-AFC9-EC323D412680 Q38287304-B290BFBF-0339-49A5-AFFC-11FBDB9E7BA0 Q38336240-47794A6F-4CCE-4806-97B0-5ED96A4F6965 Q38783950-D7FB38B1-C670-4C90-B9B1-21EC59B11F86 Q38826115-1556E9EB-6FA5-405A-9F92-A804D9B0F08F

P2860

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

http://www.wikidata.org/entity/Q28193895

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

The role of aspirin in the pre ...... motherapy for multiple myeloma

@ast

The role of aspirin in the pre ...... motherapy for multiple myeloma

@en

The role of aspirin in the pre ...... motherapy for multiple myeloma

@nl

type

label

The role of aspirin in the pre ...... motherapy for multiple myeloma

@ast

The role of aspirin in the pre ...... motherapy for multiple myeloma

@en

The role of aspirin in the pre ...... motherapy for multiple myeloma

@nl

prefLabel

The role of aspirin in the pre ...... motherapy for multiple myeloma

@ast

The role of aspirin in the pre ...... motherapy for multiple myeloma

@en

The role of aspirin in the pre ...... motherapy for multiple myeloma

@nl

P1433

Q28193895-5844D02A-C557-45CF-95B0-927671BC1148

P1476

Q28193895-6C524DCE-03F6-4520-ACDB-0876B588765E

P2093

Q28193895-5D7411E6-F134-45CB-B05E-99A7A8C53F46

Q28193895-642D6A33-A5A1-4AE8-BD87-7D50A6E338DC

Q28193895-66A56616-8A4A-4C1D-B294-5ADF9D790403

Q28193895-6C962385-825B-449E-96DF-3849EA8E9CCC

Q28193895-93F5BEC4-B72F-45F2-B5E4-4672255AD4F5

Q28193895-A11BC242-C7BA-453D-AC83-A8388D6006C1

Q28193895-A36FCB35-C5DB-4291-B3EA-5F715D44E1B6

Q28193895-DA89584B-8AAD-4CF5-BCCF-B5D6C4FBB48D

Q28193895-F62EDD6F-1C6B-49E2-9DD4-325B5573688B

Q28193895-F7044459-4920-4051-A06F-BB7FE97F3AFF

P304

Q28193895-AABCFB1F-C9CB-4109-B6D1-BEB8DD55694F

P31

Q28193895-094A411A-9690-4E82-9DBA-E80DF068057C

P3181

Q28193895-17190F5E-B968-469B-BAE7-EA27CCEB57AE

P356

Q28193895-99289B9F-9D7D-4B2B-88C5-451EDFCF7E67

P407

Q28193895-7976A098-0F9E-4CEA-916D-468A2033BFB4

P433

Q28193895-24BDFE93-CFFB-4BA6-8E7F-704D90F8F417

P478

Q28193895-08201FF2-CFD4-4F55-9F32-430EBD358F89

P50

Q28193895-1D758320-870B-498E-80A3-554CBDAC8588

P577

Q28193895-513A6362-7760-4B58-8B07-A807B806B1B8

P5875

Q28193895-492D897E-BED5-415B-8DE2-055C0A618B57

P698

Q28193895-2C007A90-142A-4B69-A7FB-3600ED27BE11

P921

Q28193895-46F28693-D126-4906-BFE6-2954D48A0C26

Q28193895-66B73DBE-F23E-4846-8F70-D6D5F25911F5

Q28193895-7E15241B-8BEC-49B3-A429-3317256D14D1

P3181

P356

P1433

Mayo Clinic Proceedings

P1476

The role of aspirin in the pre ...... motherapy for multiple myeloma

@en

P2093

Beth Faiman

http://www.w3.org/2001/XMLSchema#string

Bridget McGowan

http://www.w3.org/2001/XMLSchema#string

Erin Yiannaki

http://www.w3.org/2001/XMLSchema#string

Gordan Srkalovic

http://www.w3.org/2001/XMLSchema#string

Jerome Zeldis

http://www.w3.org/2001/XMLSchema#string

Liang Li

http://www.w3.org/2001/XMLSchema#string

Mary Ann Karam

http://www.w3.org/2001/XMLSchema#string

Mohamad A Hussein

http://www.w3.org/2001/XMLSchema#string

Rachid Baz

http://www.w3.org/2001/XMLSchema#string

Rony Abou Jawde

http://www.w3.org/2001/XMLSchema#string

P304

1568-74

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2895306

http://www.w3.org/2001/XMLSchema#string

P356

10.4065/80.12.1568

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P50

Kandice Kottke-Marchant

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7426711

http://www.w3.org/2001/XMLSchema#string

P698

16342649

http://www.w3.org/2001/XMLSchema#string

P921